Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Edwards Lifesciences Corporation

EW

The Law Offices of Todd M. Garber announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of a class (the “Class”) comprising all purchasers of the common stock of Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE:EW) between April 25, 2012 and April 23, 2013, inclusive (the “Class Period”).

Edwards Lifesciences is a medical device maker that designs and markets, among other things, artificial heart valves for implantation in patients with advanced cardiovascular disease. The Company’s SAPIEN line of transcatheter heart valves may be implanted using a minimally invasive procedure.

The Complaint alleges that the Company issued false and/or misleading statements and failed to disclose material facts related to the prospects, projected sales and adoption of the Company’s Edwards SAPIEN transcatheter aortic heart valve, including the related transfemoral and transapical delivery methods (“SAPIEN”), and related projections of financial performance for the Company’s operations. Specifically, the Complaint alleges that the defendants knew but concealed from Edwards Lifesciences’ shareholders during the Class Period that:

  • Adoption of SAPIEN was weaker than the Company claimed, due to concerns among physicians over the risks and complexity of the procedure for implanting the valve.
  • Edwards Lifesciences’ outlook for sales and earnings per share was significantly weaker than the optimistic guidance defendants offered to investors.
  • Defendants lacked a reasonable basis for the statements made concerning the Company’s operations, forecasts and outlook.

If you are a member of the above-described Class, you may move the Court no later than November 18, 2013 to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you may retain counsel of your choice or take no action and remain an absent member of the Class. If you have information or would like to learn more about these claims, or if you purchased Edwards Lifesciences shares prior to the Class Period and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M. Garber, by telephone at 213-700-7262 or by email to info@toddgarberlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today